Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in crohn's disease

Journal of Clinical Gastroenterology

Volumn 48, Issue 6, 2014, Pages 513-523

  Li, Qiurong ^a   Wang, Chenyang ^a   Tang, Chun ^a   He, Qin ^a   Li, Ning ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Crohn's disease; denaturing gradient gel electrophoresis; DNA sequencing; fungal microbiota; mucosal inflammation

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALTERNARIA BRASSICICOLA; ARTICLE; ASPERGILLUS CLAVATUS; CANDIDA ALBICANS; CANDIDA NEOFORMANS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DYSBIOSIS; ENTERITIS; FECES; FEMALE; FUNGAL COMMUNITY; FUNGUS CULTURE; FUSARIUM MONILIFORME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE FLORA; INTESTINE MUCOSA; MALE; MICROBIAL DIVERSITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SPECIES RICHNESS; ADOLESCENT; FUNGUS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROHN DISEASE; DYSBIOSIS; FECES; FEMALE; FUNGI; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84902469583     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000035     Document Type: Article

References (49)

1. Rutgeerts P, Goboes K, Peeters M, et al. Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771-774.
2. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
3. Seksik P, Sokol H, Lepage P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:11-18.
4. Marteau P, Lepage P, Mangin I, et al. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:18-23.
5. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. 2007;104:13780-13785.
6. Balfour SR. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol. 2007;41:S37-S43.
7. Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol. 1996;12: 327-333.
8. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host microbial relationships in the intestine. Science. 2001;291:881-884.
9. Bernhardt H. Candida in the ecological system of the gastrointestinal tract. Mycoses. 1996;39:44-47.
10. Bernhardt H, Knoke M. Mycological aspects of gastrointestinal microflora. Scand J Gastroenterol Suppl. 1997;222: 102-106.
11. Bernhardt H. Fungi in the intestine: normal flora or pathogens? Z Arztl Fortbild Qualitatssich. 1998;92:154-156.
12. Scanlan PD, Marches JR. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and-independent analysis of faeces. ISME J. 2008;2:1183-1193.
13. Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-841.
14. Minton K. Mucosal immunology: don't forget our fungal friends. Nat Rev Immunol. 2012;12:476-477.
15. Moyes DL, Naglik JR. Mucosal immunity and Candida albicans infection. Clin Dev Immunol. 2011;2011:307-346.
16. Kumamoto CA. Inflammation and gastrointestinal Candida colonization. Curr Opin Microbiol. 2011;14:386-391.
17. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122: 44-54.
18. Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol. 2002;37:1034-1041.
19. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55:1760-1767.
20. Zoetendal EG, von Wright A, Vilpponen-Salmela T, et al. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from faeces. Appl Environ Microbiol. 2002;68:3401-3407.
21. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
22. Chen W, Liu F, Ling Z, et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;7:e39743.
23. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24:2-6.
24. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
25. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
26. Li QR, Wang CY, Zhang Q, et al. Use of 18S ribosomal DNA polymerase chain reaction-denaturing gradient gel electrophoresis to study composition of fungal community in 2 patients with intestinal transplants. Hum Pathol. 2012;43:1273-1281.
27. Li QR, Wang CY, Tang C, et al. Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment. Am J Transplant. 2013;13:899-910.
28. Shanon CW, Weaver W. Mathematical Theory of Communication. Urbana: University of Illinois Press; 1963.
29. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003;52:237-242.
30. Thompson JD, Gibson TJ, Plewniak F, et al. The CLUS-TAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876-4882.
31. Saitou N, Nei M. The neighbour-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406-425.
32. Tamura K, Dudley J, Nei M, et al. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596-1599.
33. Guy-Grand D, Griscelli C, Vassali P. The mouse gut T lymphocyte, a novel type of T cell: nature, origin and traffic in mice in normal and graft versus-host conditions. J Exp Med. 1978;148:1661-1677.
34. Li QR, Wang CY, Tang C, et al. Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn's disease. PLoS One. 2012; 7:e34939.
35. Silva RF. Chapter 8: fungal infections in immunocompromised patients. J Bras Pneumol. 2010;36:142-147.
36. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11:30-36.
37. Ott SJ, Kuhbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008;43:831-841.
38. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696-709.
39. Muller S, Lory J, Corazza N, et al. Activated CD4+ and CD8 + cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol. 1998;152:261-268.
40. Monteleone G, Fina D, Caruso R, et al. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22:361-364.
41. Romani L. Immunity to fungal infections. Nat Rev Immonol. 2011;11:275-288.
42. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
43. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
44. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235.
45. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol. 2004;4:953-964.
46. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307: 1915-1920.
47. Cucchiara S, Stronati L, Aloi M. Interactions between intestinal microbiota and innate immune system in pediatric inflammatory bowel disease. J Clin Gastroenterol. 2012;46: S64-S66.
48. Madsen KL. Interactions between microbes and the gut epithelium. J Clin Gastroenterol. 2011;45:S111-S114.
49. Haller D. Nutrigenomics and IBD: the intestinal microbiota at the cross-road between inflammation and metabolism. J Clin Gastroenterol. 2010;44:S6-S9.